A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months (DIE-NIS)
A Multi-centre, Prospective, Non-interventional Study to Describe the Efficacy of a Continuous up to 24-week Treatment of Diphereline 3.75mg Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months.
Sponsor: Ipsen
A observational or N/A phase clinical study on Deep Infiltrating Endometriosis (DIE), this trial is completed. The trial is conducted by Ipsen and has accumulated 8 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jan 2019 — Jan 2021 [monthly]
Completed
-
Sep 2018 — Jan 2019 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Chongqing, China , Hangzhou, China , Hefei, China , Nanchang, China , Nanjing, China , Shanghai, China , Shenzhen, China , Taiyuan, China , Wuhan, China and 1 more location